Karyopharm Therapeutics Inc expected to post a loss of $4.10 a share - Earnings Preview

Karyopharm Therapeutics

01/08/2025 14:38

Karyopharm Therapeutics Inc KPTI.OQ KPTI.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The Newton Massachusetts-based  company is expected to report a 13.7% decrease in revenue to $36.935 million from $42.79 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of $4.10 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 74.6% above its last closing price of $3.81

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-4.21
-4.18
-2.77
Beat
33.7
Dec. 31 2025
-4.32
-3.92
-3.60
Beat
8.2
Sep. 30 2024
-3.76
-3.94
-3.90
Beat
1.1​
Jun. 30 2024
-4.31
-4.48
2.25
Beat
150.2
​​Mar. 31 2024
-4.93
-5.01
-4.80
Beat
4.2
Dec. 31 2023
-4.68
-4.65
-5.40
Missed
-16.2​
Sep. 30 2023
-4.26
-4.20
-4.50
Missed
-7.1
Jun. 30 2023
-5.26
-5.13
-4.35
Beat
15.3

This summary was machine generated August 1 at 13:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)